Celgene Shares Slide After Revlimid Use Expansion Curbed

By Sue Chang Markets MarketWatch Pulse

Shares of Celgene Corp. fell in Monday's extended session after the drug maker decided not the pursue approval for use of Revlimid, a lymphoma drug, in maintenance therapy following a late stage study. The clinical study had evaluated the impact of Revlimid on survival rates along with a placebo. "The interim analysis of overall survival, a key secondary endpoint, showed no benefit in the Revlimid arm," said Celgene in a statement. Celgene shed 2.4% after hours.

Continue Reading Below

Copyright © 2016 MarketWatch, Inc.